Photo of Peter Palese

Peter Palese

  • PROFESSOR & CHAIR Microbiology
  • PROFESSOR Medicine, Infectious Diseases
Print ProfilePrint Profile


  • Ph.D., University of Vienna



  • 2014 -
    Elected Fellow of the American Academy of Arts and Sciences

  • 2014 -
    Honorary Doctorate
    Baylor College of Medicine

  • 2012 -
    Sanofi–Institut Pasteur Award

  • 2012 -
    Election to the Institute of Medicine of the National Academy of Sciences

  • 2010 -
    European Virology Award (EVA)
    European Society for Virology

  • 2006 -
    Robert Koch Prize

  • 2006 -
    Elected Member
    The German Academy of Sciences Leopoldina

  • 2002 -
    Corresponding Member
    Austrian Academy of Sciences

  • 2000 -
    National Academy of Sciences


The Palese Laboratory focuses on fundamental questions concerning the genetic make-up and biology of viruses, as well as virus-host interactions.  They use molecular biological techniques to understand how viruses replicate and how they interact with cells to cause disease in their hosts.  Emphasis is on the study of RNA viruses, including influenza, paramyxo, and corona viruses.  These are four major research directions in the laboratory at the present time:  (1) by genetically changing influenza viruses via recombinant DNA techniques, they are studying viral genes and gene products to develop a universal influenza virus vaccine; (2) intracellular proteins are identified that interact with viral proteins, and the biological functions of these cellular proteins are studies; (3) attempts are made to develop broad spectrum antivirals and to identify their mechanisms of actions. 

The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.


Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR. Long-term survival of influenza virus infected club cells drives immunopathology. The Journal of Experimental Medicine 2014 Aug; 211(9).

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, García-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America 2014 Sep; 111(36).

Miller MS, Palese P. Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 2014 Apr; 157(2).

DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nature Medicine 2014 Feb; 20(2).

Krammer F, Palese P. Universal influenza virus vaccines: need for clinical trials. Nature Immunology 2014 Jan; 15(1).

Heaton NS, Sachs D, Chen CJ, Hai R, Palese P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proceedings of the National Academy of Sciences of the United States of America 2013 Dec; 110(50).

Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, García-Sastre A, Palese P. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. Journal of Virology 2013 Oct; 87(19).

Martinez-Gil L, Alamares-Sapuay JG, Ramana Reddy MV, Goff PH, Premkumar Reddy E, Palese P. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Antiviral Research 2013 Oct; 100(1).

Chou YY, Heaton NS, Gao Q, Palese P, Singer RH, Singer R, Lionnet T. Colocalization of different influenza viral RNA segments in the cytoplasm before viral budding as shown by single-molecule sensitivity FISH analysis. PLoS Pathogens 2013; 9(5).

Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annual Review of Medicine 2013; 64.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Palese during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Avimex; Farmak; Genentech, Inc.; Gilead Sciences, Inc.; MedImmune, LLC

Scientific Advisory Board:

  • MedImmune, LLC

Royalty Payments:

  • Avimex; MedImmune, LLC

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • ContraFect Corporation; Vivaldi Biosciences Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Annenberg Building Floor 16 Room 16-20
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-7318
Fax: 212-722-3634